Compare Incyte Corporation (INCY) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs 3M Company — how do they compare? Incyte Corporation trades at $117.7 (market cap $23.11B), while 3M Company trades at $174.75 (market cap $82.99B). The key difference: 3M Company is far larger — about 3.6× Incyte Corporation's market cap, and 3M Company pays a 1.96% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MMM | |
|---|---|---|
Market Cap | $23.11B | $82.99B |
Sector | Health | Industrials |
52-Week High | $118.52 | $174.61 |
52-Week Low | $67.38 | $141.10 |
Enterprise Value | $19.13B | $91.39B |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
3M (MMM) trades at $159.98, up 0.09% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.14, exceeding the $1.98 estimate, and maintains a strong net income margin of 11.14%. Analysts are divided with a 48.49% buy rating, and the consensus price target is $149.75. Recent news highlights Q2 earnings expectations and new partnerships, such as the Airbus A220 supply agreement.
The outlook for MMM is mixed; earnings momentum and cost optimization support growth, but valuation ratios like a P/E of 30.8 suggest premium pricing. Risks include consumer segment weakness and debt levels. Upside depends on Q2 results meeting the $2.27 EPS forecast, while downside could stem from macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
